Stryker Co. (NYSE:SYK) has received an average rating of “Buy” from the twenty-nine analysts that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, eight have given a hold recommendation, seventeen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $212.67.
Several equities research analysts have recently commented on SYK shares. Morgan Stanley lifted their price objective on shares of Stryker from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. UBS Group lowered their price objective on shares of Stryker from $230.00 to $202.00 and set a “neutral” rating for the company in a research note on Friday, May 1st. Barclays downgraded shares of Stryker from an “equal weight” rating to an “underweight” rating and set a $155.00 price objective for the company. in a research note on Monday, April 13th. Oppenheimer restated a “hold” rating and set a $200.00 target price on shares of Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. decreased their target price on shares of Stryker from $240.00 to $210.00 and set an “overweight” rating for the company in a research report on Wednesday, April 15th.
In other news, CFO Glenn S. Boehnlein sold 10,351 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $185.24, for a total transaction of $1,917,419.24. Following the completion of the sale, the chief financial officer now owns 16,321 shares of the company’s stock, valued at $3,023,302.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 7,299 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $193.23, for a total transaction of $1,410,385.77. Following the sale, the director now directly owns 13,972 shares of the company’s stock, valued at approximately $2,699,809.56. The disclosure for this sale can be found here. Insiders have sold 30,670 shares of company stock valued at $5,775,251 in the last three months. Corporate insiders own 6.80% of the company’s stock.
NYSE SYK traded up $3.76 on Tuesday, hitting $177.52. The stock had a trading volume of 2,223,900 shares, compared to its average volume of 2,070,250. Stryker has a 52-week low of $124.54 and a 52-week high of $226.30. The business’s fifty day moving average price is $189.11 and its 200 day moving average price is $192.42. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.58 and a quick ratio of 1.77. The stock has a market cap of $66.54 billion, a price-to-earnings ratio of 31.20, a price-to-earnings-growth ratio of 3.04 and a beta of 0.85.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $1.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.69 by $0.15. Stryker had a net margin of 14.47% and a return on equity of 24.90%. The business had revenue of $3.59 billion during the quarter, compared to the consensus estimate of $3.45 billion. During the same period in the previous year, the firm posted $1.88 earnings per share. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stryker will post 6.22 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.575 dividend. The ex-dividend date is Monday, June 29th. This represents a $2.30 dividend on an annualized basis and a dividend yield of 1.30%. Stryker’s dividend payout ratio (DPR) is currently 27.85%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Read More: What is Depreciation?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.